Cure8 news brief
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm the findings.
Adult patients with moderate-to-severe UC or CD, clinicians who treat IBD, researchers tracking new IBD drugs, and patients on biologic or advanced therapies
Teva and Sanofi reported Phase 2b results for duvakitug (an anti-TL1A monoclonal antibody) presented at ECCO 2025.
In the RELIEVE UCCD study, duvakitug achieved higher clinical remission rates than placebo in ulcerative colitis (36% at 450 mg; 48% at 900 mg vs 20% placebo at week 14) and higher endoscopic response rates in Crohn’s disease (26% at 450 mg; 48% at 900 mg vs 13% placebo at week 14).
Results were reported across both advanced-therapy–experienced and therapy-naïve subgroups, and the companies said the treatment was generally well tolerated with no new safety signals.
This is company-reported Phase 2b data presented at ECCO; Phase 3 trials were announced to start in H2 2025. Full peer-reviewed data or conference abstracts should be consulted for details on endpoints, subgroups, and safety.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
